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TRANSFUSION COMPLICATIONS
West Nile virus blood transfusion-related infection despite nucleic
acid testing
Alexandre Macedo de Oliveira, Brady D. Beecham, Susan P. Montgomery, Robert S. Lanciotti,
Jeffrey M. Linnen, Cristina Giachetti, Larry A. Pietrelli, Susan L. Stramer, and Thomas J. Safranek

BACKGROUND: A case of West Nile virus (WNV)
encephalitis associated with transfusion of blood that did
not react when tested for WNV by minipool (MP) nucleic
acid testing (NAT) is described. A Nebraska man
developed clinical encephalitis 13 days after surgery and
transfusion of 26 blood components. Antibody testing
confirmed WNV infection. An investigation was initiated to
determine the source of this infection.
STUDY DESIGN AND METHODS: The patient’s family
members were interviewed to identify risk factors for WNV
infection. Residual samples were retested for WNV RNA
using transcription-mediated amplification (TMA) assay
and two polymerase chain reaction (PCR) assays. Blood
donors’ follow-up serum samples were collected. All
samples were tested for WNV-specific immunoglobulin M
antibodies.
RESULTS: The patient’s family denied recent mosquito
exposure. The 20 blood components collected after July
2003 did not react when tested for WNV in a six-member
MP-NAT at the time of donation. Retrospective individual
testing identified one sample as WNV-reactive by the TMA
assay and one of the PCR assays. Seroconversion was
demonstrated in the donor associated with this sample.
CONCLUSION: WNV RNA detection by individual
donation NAT demonstrates viremic blood escaping MPNAT and supports transfusion-related WNV transmission.
MP-NAT may not detect all WNV-infected blood donors,
allowing WNV transmission to continue at low levels. WNV
NAT assays might vary in sensitivity and pooling
donations could further impact test performance.
Understanding MP NAT limitations can improve strategies
to maintain safety of the blood supply in the United States.

W

est Nile virus (WNV), a mosquito-borne
flavivirus, was initially seen in the US in
1999 and first reported among Nebraska
residents in 2002.1,2 Humans serve as incidental hosts, and most infections are asymptomatic;
approximately 30 percent of infections result in a nonneuroinvasive disease known as West Nile fever, and less
than 1 percent of infected individuals develop severe diseases such as meningitis and/or encephalitis.3-5 In the US,
a total of 9862 human cases of WNV disease were reported
in 45 states and the District of Columbia in 2003. Nebraska
reported more than 1900 human WNV cases in 2003, ranking second only to Colorado.6 Blood transfusion-related
transmission of WNV infection during the 2002 US epidemic prompted rapid development of two investigational nucleic acid testing (NAT) assays to screen donated
blood for WNV viremia: the TaqScreen WNV test (Roche

ABBREVIATIONS: IDT = individual donation testing; IND =
investigational new drug; MP(s) = minipool(s); PRNT = plaque
reduction neutralization test; SLE = St Louis encephalitis; WNV =
West Nile virus.
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Molecular Systems Inc., Pleasanton, CA) and the Procleix
WNV assay (Gen-Probe Inc., San Diego, CA).7,8 (Use of
trade names is for identification purposes only and does
not constitute endorsement by the US Public Health Service or the Centers for Disease Control and Prevention
[CDC].) The tests were implemented between June and
August 2003.9,10 Because of automation constraints, the
tests are performed with minipools (MPs) of either six
(TaqScreen assay) or 16 (Procleix assay) donations. A limited number of blood centers have the capacity to routinely screen by individual donation testing (IDT); in
addition, some programs converted to IDT for limited
periods during the 2003 epidemic. Donated blood from
reactive pools is individually retested to identify the WNVreactive donation. Donors associated with WNV-reactive
individual tests are deferred from donation for at least
4 weeks. The WNV-reactive donation and any of that
donor’s unexpired blood components obtained in the
28 days before the reactive tests are discarded. In this
report, we describe the investigation of a patient who
developed WNV encephalitis after receiving blood that
had did not react with NAT for WNV in a six-member MP.

CASE REPORT

neutralization test (PRNT) and negative for the presence
of St Louis encephalitis (SLE) by PRNT at the CDC
(Table 1).
Upon receipt of the first positive WNV IgM test, the
hospital infection-control practitioners notified the Office
of Epidemiology at the Nebraska Health and Human Services System and an investigation was launched to determine the source of this infection.

MATERIALS AND METHODS
Family members of the infected patient were interviewed
in August 2003 to evaluate the potential for mosquito
exposure after surgery. In addition, all transfused blood
components were identified and traced to their donors.
Residual samples from the donation testing tubes and
unused co-components were located and stored frozen
(-20∞C). Implicated donors were interviewed about symptoms consistent with WNV infection, and a follow-up
blood sample was collected in September 2003.
Quarantined residual samples were tested individually for the presence of WNV RNA with three different laboratory tests: the two investigational assays used for WNV
blood donor screening and an in-house assay. The tests
were a transcription-mediated amplification assay (Procleix WNV assay, Gen-Probe Inc.) and two different
dynamic quantitative polymerase chain reaction (PCR)
assays: TaqScreen WNV test (Roche Molecular Systems
Inc.) and an in-house PCR (CDC, Fort Collins, CO).11-13
Reactive specimens were further tested with the commercial assays: 10 replicates with undiluted samples and 10

On August 4, 2003, an 80-year-old Nebraska man underwent open-heart surgery. During surgery, the patient
received 26 blood components because of massive bleeding: 8 units of red blood cells, 6 units of fresh frozen
plasma (FFP), 2 units of single-donor platelets (PLTs), and
10 units of random-donor PLTs. The patient recovered and
was discharged to home 10 days later.
On August 19, 2003, 15 days after transTABLE 1. Laboratory tests performed on the index patient at time
fusion, the patient was rehospitalized
of readmission and convalescence, Nebraska, 2003
after experiencing mental confusion
Laboratory study
Collection date
Result
Normal values
and fever for 2 days. The patient’s conHemoglobin (g/100 mL)
8/20/2003
13.5-17.0
11
dition worsened, and he was placed on
WBC count (¥103 cells/mm3)
8/20/2003
9
4-10
ventilatory support for 3 weeks. His
Differential (%)
Neutrophils
57
40-80
condition gradually improved, and he
Lymphocytes
39
20-45
was subsequently transferred to a rehaMonocytes
3
0-10
bilitation facility.
Eosinophils
1
0-7
Basophils
0
0-2
WNV encephalitis was suspected,
Serum
and serum and cerebrospinal fluid were
Glucose (mg/dL)
8/20/2003
103
65-120
collected during the second hospitalizaProtein (g/dL)
8/20/2003
6.1
6.0-8.3
CSF*
tion. These tested positive for the presGlucose (mg/dL)
8/20/2003
58
<105
ence of WNV-specific immunoglobulin
Protein (mg/dL)
8/20/2003
98.4
<42
M (IgM) antibodies at the Nebraska
WBC count (cells/mm3)
8/20/2003
155
<3
Mononuclear (%)
39
Public Health Laboratory (Table 1).
Segmented neutrophils (%)
61
On September 10, 2003, 37 days
Arbovirus studies
after transfusion, a convalescent serum
WNV IgM (serum)
8/20/2003
Positive
Negative
WNV IgM (CSF)
8/20/2003
Positive
Negative
sample was collected from the patient.
WNV IgM (serum)
9/10/2003
Positive
Negative
This sample tested positive for the presWNV PRNT
9/10/2003
Positive
Negative
ence of WNV by WNV-specific IgM
SLE PRNT
9/10/2003
Negative
Negative
enzyme-linked immunosorbent assay
* CSF = cerebrospinal fluid.
(ELISA) and WNV plaque reduction
1696
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with MP-dilution levels (1:6 for the TaqScreen assay and
1:16 for the Procleix assay). Viral load of reactive specimens was determined by quantitative PCR (SuperQuant
for WNV, National Genetics Institute, Los Angeles, CA) and
through dilutional studies at CDC and Gen-Probe Inc.
Residual samples from donations and follow-up samples were tested with WNV IgM antibody-capture ELISA.
WNV infection was confirmed with PRNT for WNV and
SLE.14

RESULTS
Exposure assessment
Family members denied recent mosquito exposure,
reporting that the patient was hospitalized or bedridden
at home during the 2 weeks before symptom onset. The
infected patient received 26 blood components from 26
different donors. These donations generated 41 additional
blood components: 18 were transfused to other patients,
17 were quarantined, and 6 were discarded before our
investigation began.
Six of the 26 donations took place in February 2003
and had no residual samples available at the time of investigation. The remaining 20 donations were made in July
and August 2003. Thirteen of these had approximately
200 mL of quarantined FFP available for testing; the other
7 had approximately 2 mL of serum remaining.

Gen-Probe Inc., respectively. Replicate results with the
Procleix assay showed reactivity in all 10 replicates with
undiluted samples and in 3 of 10 at 1:16 dilution. The
TaqScreen assay exhibited reactivity in 5 of 10 and 2 of 10
replicates at undiluted and 1:6-diluted samples, respectively. This donation generated 1 unit of PLTs, which was
transfused to the index patient. The other 12 high-volume
samples did not react in all NAT assays.
The seven 2-mL specimens were aliquotted and sent
to CDC and the other test developers’ laboratories. They
all did not react by the CDC PCR and the Procleix assay.
Volume was insufficient for the TaqScreen assay.
WNV-specific IgM was negative for all 20 donations
that had residual samples available for testing. Test results
are shown in Table 2.

Donor follow-up
We obtained follow-up samples from 24 of the 26 donors
in mid-September 2003 and tested these for WNV-specific
IgM antibodies. The median interval between donation
and follow-up sample collection was 44 days (range, 38219 days). The donor associated with the NAT-positive
sample (Donor A) and two other donors tested positive for
IgM antibodies (Table 2). Confirmatory PRNT tests were
positive for the presence of WNV and negative for the presence of SLE on these three samples. These three donors
denied WNV symptoms during the 30 days before and
after donation.

Results from donations
The CDC PCR, the investigational TaqScreen assay, and
the investigational Procleix assay were all carried out on
the 13 high-volume specimens by the developers of each
test. One specimen reacted by the Procleix assay, equivocal by the CDC PCR, and did not react by the TaqScreen
assay. A subsequent CDC PCR assay with an increased
RNA extraction volume reacted. The viral load in this sample was estimated to be 560 copies per mL by the SuperQuant assay and 40 and 30 copies per mL by CDC and

Blood co-components from WNV-specific
IgM-positive donors
The two additional blood components derived from
Donor A’s donation were not transfused. Units from the
other two IgM-positive donors were transfused to two
other patients. Both recipients were asymptomatic for
WNV. One tested negative for the presence of WNV IgM,
and the other declined testing.

TABLE 2. Test results obtained on donated blood and follow-up samples for the 26 donors, Nebraska, 2003
Donor
A
B
C
D-M
N
O-T
U-Y‡
Z‡

WNV IgM
Negative
Negative
Negative
Negative
Negative
Negative
NA
NA

Original donation
CDC PCR
Procleix assay
Reactive*
Reactive
Did not react
Did not react
Did not react
Did not react
Did not react
Did not react
Did not react
Did not react
Did not react
Did not react
NA
NA
NA
NA

TaqScreen assay
Did not react
Did not react
NA†
Did not react
Did not react
NA
NA
NA

WNV IgM
Positive
Positive
Positive
Negative
NA
Negative
Negative
NA

Follow-up sample
WNV PRNT
Positive
Positive
Positive
NA
NA
NA
NA
NA

SLE PRNT
Negative
Negative
Negative
NA
NA
NA
NA
NA

* Test performed using high extraction volume.
† NA = not available.
‡ Donations from February 2003.
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DISCUSSION
This investigation describes a patient with WNV encephalitis acquired through transfusion of WNV viremic blood
that went undetected by MP-NAT screening but reacted
for WNV by IDT. Our conclusion is supported by the detection of WNV RNA in one of the donations, followed by
seroconversion in the corresponding donor. The implicated donor never developed symptomatic WNV infection. WNV RNA likely was present at levels below the
detection limit of the MP format.
Although this investigation suggests WNV blood
transfusion-related infection, it has three main limitations. First, the infected patient could have contracted
WNV before surgery. Because no presurgical samples from
the infected patient were available for testing, excluding
existing infection was impossible. Second, it was not possible to rule out mosquito exposure as the mode of transmission. The patient denied symptoms before surgery,
however, and his convalescent condition kept him hospitalized or indoors at home, making this other source of
infection unlikely. Finally, because two other seroconversions were documented among these donors, we cannot
exclude the possibility of an alternate-source donor.
Recipients of co-components, however, from donated
blood from the seroconverters did not experience WNV
symptoms, nor was WNV RNA identified in residual samples from their donations. The high incidence of WNV
infection in Nebraska during summer 2003 makes it possible that these persons were infected after donating
blood.
Although the six donations from February 2003 were
not available for NAT, these donations occurred before
WNV was circulating in Nebraska. In addition, follow-up
samples from five of these donors were negative for the
presence of WNV-specific IgM antibodies, making them
an unlikely source of infection.
WNV blood transfusion-related infections were first
described during the 2002 epidemic.7,8 To minimize this
risk, the Food and Drug Administration (FDA) recommended deferring donors reporting fever with headache
in the week before donation.15 In addition to the clinical
screening, beginning June 2003, NAT was introduced as
a blood-screening tool with protocols conducted under
FDA’s investigational new drug (IND) mechanisms.9,10
Recognizing technology and resource constraints, the IND
protocols allowed for blood donation screening in MPs of
6 (TaqScreen assay) or 16 (Procleix assay) members. Pooling donations may reduce assay sensitivity and increase
the possibility of missing donors with low-level viremia.
In this report, the six-member MP TaqScreen assay
performed on the donations did not react, and the blood
products were released for use in accordance with the IND
protocol. A patient developed WNV encephalitis 13 days
after transfusion with these products, a time frame com1698
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patible with WNV’s incubation period. Residual samples
from these donations were subsequently retested at three
laboratories. For one donation, samples tested with replicate tests inconsistently reacted by the TaqScreen assay
but reacted by the Procleix assay. Viral quantitation of that
sample detected low levels of WNV RNA, although variability among quantitative results was observed. Dilutional testing showed that the MP format compromised
test performance compared with IDT. The replicate testing also indicated that differences in sensitivity might
exist between the investigational NAT assays. Further
evaluation is necessary to confirm these conclusions.
The timely development of WNV NAT and its implementation under the IND mechanism are the result of
an extraordinary effort by commercial laboratories, CDC,
FDA, and the blood-collection community to enhance the
safety of the blood supply in the US. In 2003, a total of 818
US blood donations were identified as “presumed
viremic,” which is defined as repeat reactivity on the same
or on a different NAT assay.16 The high number of viremic
donors with asymptomatic WNV infection highlights the
need for highly sensitive WNV-specific NAT to ensure
blood supply safety. In addition, strategies such as the
implementation of IDT in regions with high WNV infection rates should be considered.
NAT for human immunodeficiency virus-1 and hepatitis C virus has improved the identification of infected
donors and is universally performed by the US blood
industry, although it has been demonstrated to be costineffective by traditional expenditure versus benefit
estimates for medical interventions.17-19 NAT could be
cost-effective for WNV screening of the blood supply,
because seasonal incidence is high in certain geographic
areas, infection is asymptomatic in more than 80 percent
of cases, and long periods of viremia can occur.20,21
WNV can be effectively transmitted through blood
transfusions. The burden of WNV blood transfusionrelated disease is probably underestimated owing to the
low rate of symptomatic disease among recipients and the
difficulty in establishing blood transfusion as the source
of WNV infection.8 The presence of infectious WNV in
donated blood necessitates the application of viral detection testing such as NAT. Additional studies are needed to
define the sensitivity of current NAT assays, their ability
to detect low-level viremic donations, and their costeffectiveness. This would allow optimization of testing
protocols.
Emerging infectious diseases pose risks to blood
safety.22 Health-care workers and public-health authorities
should maintain surveillance for the possibility of WNV
and other arboviral transmission through blood transfusions. The development and implementation of WNV NAT
for blood screening has contributed to a decreased risk of
blood-borne transmission in the US. Nevertheless, lowviremic donors may go undetected by MP-NAT.
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